Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Subcutaneous and Intravenous LY3537031 in Healthy Participants
NCT07202871Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2025
- Primary completion
- Jul 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1 trial of LY3537031 in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration versus Time Curve and Maximum Serum Observed Drug Concentration. Started Nov 2025; status: completed.
02
Drugs
LY3537031
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT07202871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07202871.